Compositions and methods for the improved production and delivery of RNA by efficient transcription termination

Patent metadata

Field	Value
Publication number	US-11647753-B2
Application number	US-201916434854-A
Country	US
Kind code	B2
Filing date	Jun 7, 2019
Priority date	Mar 15, 2013
Publication date	May 16, 2023
Grant date	May 16, 2023

Abstract

Compositions and methods for efficiently producing and delivering double stranded RNA (dsRNA) are provided. Vector constructs useful for in vitro and in vivo expression of dsRNA are described. Also described are cell expression systems for efficient and cost-effective production of dsRNA in living cells and methods and compositions for providing the expressed dsRNA to target organisms. The described compositions and methods can be used to produce RNA molecules for screening or other uses, and to amplify RNA sequences for analysis.

First claim

What is claimed is:

1. An engineered expression construct comprising:
a. a promoter;
b. a first nucleic acid sequence positioned transcriptionally downstream of the promoter, wherein the first nucleic acid sequence encodes a double-stranded RNA (dsRNA) or a protein; and
c. a second nucleic acid sequence, positioned 3′ to the first nucleic acid sequence, wherein the second nucleic acid sequence comprises a rrn BT2 transcription terminator sequence, a first PET transcription terminator sequence, a PTH transcription terminator sequence, and a second PET transcription terminator sequence;

wherein the first nucleic acid sequence and the second nucleic acid sequence are operably linked to the promoter.

2. The engineered expression construct of claim 1 , wherein
a. the rrn BT2 transcription terminator sequence comprises SEQ ID NO: 9;
b. the PTH transcription terminator sequence comprises a sequence selected from the group consisting of SEQ ID NOs: 6 and 7; or
c. the first PET transcription terminator sequence, the second PET transcription terminator sequence, or both, comprises SEQ ID NO: 5.

3. The engineered expression construct of claim 1 , wherein the rrn BT2 transcription terminator sequence, the first and second PET transcription terminator sequences, and the PTH transcription terminator sequence each comprise a hairpin.

4. The engineered expression construct of claim 3 , wherein the hairpins are separated by a spacer region comprising ten or fewer nucleotides.

5. The engineered expression construct of claim 3 , wherein the hairpins comprise a stem region with fewer than three unpaired nucleotides.

6. The engineered expression construct of claim 1 , wherein the promoter is selected from the group consisting of a T7 promoter, a T3 promoter, a SV40 promoter, a T5 promoter, a β-lactamase promoter, an Escherichia coli galactose promoter, an arabinose promoter, an alkaline phosphatase promoter, a tryptophan promoter, a lactose (lac) operon promoter, a lacUV5 promoter, a trc promoter, and a tac promoter.

7. The engineered expression construct of claim 1 , wherein the promoter is selected from the group consisting of an RNA Pol I promoter, an RNA Pol II promoter, and an RNA Pol III promoter.

8. The engineered expression construct of claim 7 , wherein the RNA Pol III promoter is selected from the group consisting of a U6 promoter, a tRNA promoter, a retroviral LTR promoter, an adenovirus VA1 promoter, a 5S rRNA promoter, a 7SK RNA promoter, a 7SL RNA promoter, and an H1 RNA promoter.

9. The engineered expression construct of claim 1 , wherein transcription of the construct achieves a termination efficiency of at least 60%.

10. An isolated host cell comprising an engineered expression construct comprising:
a. a promoter;
b. a first nucleic acid sequence positioned transcriptionally downstream of the promoter, wherein the first nucleic acid sequence encodes a double-stranded RNA (dsRNA) or a protein; and
c. a second nucleic acid sequence, positioned 3′ to the first nucleic acid sequence, wherein the second nucleic acid sequence comprises a rrn BT2 transcription terminator sequence, a first PET transcription terminator sequence, a PTH transcription terminator sequence, and a second PET transcription terminator sequence;

wherein the first nucleic acid sequence and the second nucleic acid sequence are operably linked to the promoter.

11. The isolated host cell of claim 10 , wherein
a. the rrn BT2 transcription terminator sequence comprises SEQ ID NO: 9;
b. the PTH transcription terminator sequence comprises a sequence selected from the group consisting of SEQ ID NOs: 6 and 7; or
c. the first PET transcription terminator sequence, the second PET transcription terminator sequence, or both, comprises SEQ ID NO: 5.

12. The isolated host cell of claim 10 , wherein the isolated host cell is a bacterial host cell.

13. The isolated host cell of claim 12 , wherein the bacterial host cell does not express RNase A.

14. The isolated host cell of claim 12 , wherein the bacterial host cell is of a genus selected from the group consisting of Acetobacter, Acinetobacter, Agrobacterium, Alcaligenes, Alicyclobacillus, Anabaena, Anacystis, Arthrobacter, Azotobacter, Bacillus, Bifidobacterium, Brevibacterium, Butyrivibrio, Buchnera, Campestris, Campylobacter, Chromatium, Clostridium, Coprococcus, Corynebacterium, Enterococcus, Enterobacter, Escherichia, Erwinia, Faecalibacterium, Flavobacterium, Francisella, Fusobacterium, Geobacillus, Haemophilus, Helicobacter, Ilyobacter, Klebsiella, Lactobacillus, Lactococcus, Leuconostoc, Mesorhizobium, Methylobacterium, Methylophilus, Microbacterium, Mycobacterium, Neisseria, Pantoea, Prochlorococcus, Pseudomonas, Rhizobium, Rhodobacter, Rhodococcus, Rhodopseudomonas, Rhodospirillum, Roseburia, Salmonella, Scenedesmus, Shigella, Serratia, Staphylococcus, Streptococcus, Streptomyces, Synechococcus, Thermoanaerobacterium, Thermococcus, Thermosynechococcus, Tropheryma, Ureaplasma, Xanthomonas, Xylella, Yersinia, Zanthomonas , and Zymomonas.

15. The isolated host cell of claim 10 , wherein the isolated host cell is a eukaryotic cell.

16. The isolated host cell of claim 15 , wherein the eukaryotic cell is selected from the group consisting of a fungal cell, a plant cell, an insect cell, an amphibian cell, an avian cell, and a mammal cell.

17. The isolated host cell of claim 16 , wherein the fungal cell is a yeast cell.

18. The isolated host cell of claim 10 , wherein the promoter is selected from the group consisting of a T7 promoter, a T3 promoter, a SV40 promoter, a T5 promoter, a β-lactamase promoter, an Escherichia coli galactose promoter, an arabinose promoter, an alkaline phosphatase promoter, a tryptophan promoter, a lactose (lac) operon promoter, a lacUV5 promoter, a trc promoter, and a tac promoter.

19. The isolated host cell of claim 10 , wherein the promoter is selected from the group consisting of an RNA Pol I promoter, an RNA Pol II promoter, and an RNA Pol III promoter.

20. The isolated host cell of claim 19 , wherein the RNA Pol III promoter is selected from the group consisting of a U6 promoter, a tRNA promoter, a retroviral LTR promoter, an adenovirus VA1 promoter, a 5S rRNA promoter, a 7SK RNA promoter, a 7SL RNA promoter, and an H1 RNA promoter.

Assignees

• Monsanto Technology Llc

Inventors

• Baum James A
• Christian Allen T
• Evdokimov Artem
• Moshiri Farhad
• Weaver Lisa Marie
• Zhang Haitao

Classifications

• A01H3/00

  Processes for modifying phenotypes {, e.g. symbiosis with bacteria} (A01H4/00 takes precedence) · CPC title

• C12N15/72

  Expression systems using regulatory sequences derived from the lac-operon · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N15/67

  General methods for enhancing the expression · CPC title

• A01N63/60 Primary

  Isolated nucleic acids · CPC title